Bristol-Myers Squibb

Bristol-Myers to Buy MyoKardia for $13B
Celgene to Sell Otezla for $13.4B
‘Threats’ to McKesson Don’t Hold Up
Bristol-Myers to Buy Big Pharma Rival Celgene
What Wildfires, Hurricanes Can Teach About Risk Reduction
Bristol-Myers Squibb Settles FCPA Charges
Strong Dollar Deflates Earnings
The Companies That Pay the Slowest
Drug Prices: Costly Cures